EPO and anemia (phenotype): Beyond the renal effects of glycosuria and natriuresis, SGLT2 inhibitors also offer broad metabolic benefits, including reduction in visceral, liver, and epicardial fat by shifting substrate utilization from carbohydrates to lipids and ketone bodies [16–20], decreased serum uric acid levels and lowered risk of gout flares via enhanced renal uric acid excretion [21, 22], reduced kidney stone formation by increasing urine citrate levels [23–26], and alleviation of anemia by increasing erythropoietin production and suppressing proinflammatory pathways [27].